Cardiex (ASX:CDX), an Australian health technology company, has announced the completion of the HEARTsense Wearable Study. The company has also secured another US wearable patent for its wearable biomarker technology, implemented as a wearable blood pressure monitor.
Successful Completion of HEARTsense Wearable Study
The engineers and researchers at Cardiex have finalized their primary study that validated the use of the company’s SphygmoCor® biomarker technology in wearable devices. SphygmoCor is the global “gold standard” in the measurement of central blood pressure, arterial stiffness, vascular aging, and multiple other clinically relevant biomarkers.
Speaking to Bloodpressure.Me, Cardiex CEO Craig Cooper said:
“Our biomarker technology has been used in over 2300 research studies, 47 clinical trials and is in all top 20 US hospitals, with 4000+ global clinical installations. It’s that same level of accuracy and validation that we are now making available for wearables in multiple device formats”.
Completion of the HEARTsense study is a key step for Cardiex as it prepares to lodge its FDA submission for clearance of its wearable technology.
Results of the HEARTsense Study are now being submitted for publication in leading peer-reviewed journals.
Cardiex Secures US Wearable Patent
Cardiex has also just been awarded another patent for a wearable blood pressure monitor. The title of the patent is WEARABLE DEVICE WITH PHOTOPLETHYSMOGRAM SENSOR.
This new Cardiex wearable patent employs a PPG sensor to capture key biometric indicators of disease using arterial signals from the fingertip and builds upon the existing patent portfolio the company already has in the wearable space.
Speaking to Bloodpressure.me, Cardiex CEO Craig Cooper said:
“We believe our focus on medical grade and FDA cleared arterial biomarkers is what gives us a competitive advantage in the wearable space.
We invented the technology to non-invasively measure central pressure biomarkers over 20 years ago and later this year we anticipate announcing FDA clearances of those same biomarkers using a PPG sensor in a wearable format.
Central pressure waveforms allow medical grade accuracy of vascular health including arterial stiffness, pulse pressures, heart stress, and central blood pressure, to name a few”.
Cooper also told Bloodpressure.Me that the company had received multiple inbound enquiries about integrating their technology into existing market-leading wearable devices.
